Karyopharm Therapeutics
KPTI
149 hedge funds and large institutions have $303M invested in Karyopharm Therapeutics in 2022 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 39 increasing their positions, 58 reducing their positions, and 13 closing their positions.
144% more call options, than puts
Call options by funds: $4.7M | Put options by funds: $1.92M
115% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 13
7% more funds holding
Funds holding: 139 → 149 (+10)
0.12% less ownership
Funds ownership: 5.75% → 5.63% (-0.12%)
33% less repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 58
39% less capital invested
Capital invested by funds: $499M → $303M (-$197M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
+$10.2M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$5.28M |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$4.85M |
| 4 |
ECM
ExodusPoint Capital Management
New York
|
+$3.83M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
+$3.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
-$9.94M |
| 2 |
ITP
Iron Triangle Partners
Cos Cob,
Connecticut
|
-$5.5M |
| 3 |
Millennium Management
New York
|
-$3.96M |
| 4 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$3.95M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$3.89M |
KPTI Hedge Fund Activity: Q2 2022 in Review
149 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q2 2022, worth a combined $303M — down 39% from $499M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new KPTI positions and 13 closed out — a net gain of 15 holders — while 39 added to existing stakes and 58 trimmed.
The largest buyer was Walleye Capital, adding an estimated $10.2M. The largest seller was Commodore Capital, cutting an estimated $9.94M.
- 149 institutional investors held Karyopharm Therapeutics (KPTI) as of Q2 2022, up from 139 in Q1 2022.
- Funds reported $303M of Karyopharm Therapeutics stock for Q2 2022, down 39% quarter-over-quarter.
- 28 funds opened new Karyopharm Therapeutics positions in Q2 2022 and 13 closed out, a net change of +15 holders.
- The largest Karyopharm Therapeutics buyer in Q2 2022 was Walleye Capital, an estimated $10.2M added.
- The largest Karyopharm Therapeutics seller in Q2 2022 was Commodore Capital, an estimated $9.94M sold.
Based on aggregated 13F filings for Q2 2022.